Doxecitine; doxribtimine - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for doxecitine; doxribtimine and what is the scope of patent protection?
Doxecitine; doxribtimine
is the generic ingredient in one branded drug marketed by Ucb Inc and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.One supplier is listed for this compound.
Summary for doxecitine; doxribtimine
| International Patents: | 64 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | doxecitine; doxribtimine at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for doxecitine; doxribtimine
Generic Entry Date for doxecitine; doxribtimine*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
FOR SOLUTION;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for doxecitine; doxribtimine
US Patents and Regulatory Information for doxecitine; doxribtimine
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | KYGEVVI | doxecitine; doxribtimine | FOR SOLUTION;ORAL | 219792-001 | Nov 3, 2025 | RX | Yes | Yes | 10,471,087 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ucb Inc | KYGEVVI | doxecitine; doxribtimine | FOR SOLUTION;ORAL | 219792-001 | Nov 3, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ucb Inc | KYGEVVI | doxecitine; doxribtimine | FOR SOLUTION;ORAL | 219792-001 | Nov 3, 2025 | RX | Yes | Yes | 11,649,259 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for doxecitine; doxribtimine
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2016280293 | ⤷ Start Trial | |
| Australia | 2020204042 | ⤷ Start Trial | |
| Australia | 2021250841 | ⤷ Start Trial | |
| Brazil | 112017027079 | ⤷ Start Trial | |
| Brazil | 122020021913 | ⤷ Start Trial | |
| Canada | 2989653 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for doxecitine; doxribtimine
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3310362 | 301385 | Netherlands | ⤷ Start Trial | PRODUCT NAME: DOXECITINE EN DOXRIBTIMINE; REGISTRATION NO/DATE: EU/1/25/2013 20260327 |
| 3310362 | CR 2026 00027 | Denmark | ⤷ Start Trial | PRODUCT NAME: DOXECITIN OG DOXRIBTIMIN; REG. NO/DATE: EU/1/25/2013 20260327 |
| 3310362 | C20265012 | Finland | ⤷ Start Trial | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
